Frontiers in Public Health (Aug 2022)
The impact of HMG-CoA reductase inhibitors use on the clinical outcomes in critically ill patients with COVID-19: A multicenter, cohort study
- Khalid Al Sulaiman,
- Khalid Al Sulaiman,
- Khalid Al Sulaiman,
- Khalid Al Sulaiman,
- Ohoud Aljuhani,
- Ghazwa B. Korayem,
- Ali F. Altebainawi,
- Shmeylan Al Harbi,
- Shmeylan Al Harbi,
- Shmeylan Al Harbi,
- Abdulrahman Al Shaya,
- Abdulrahman Al Shaya,
- Abdulrahman Al Shaya,
- Hisham A. Badreldin,
- Hisham A. Badreldin,
- Hisham A. Badreldin,
- Raed Kensara,
- Raed Kensara,
- Abdullah F. Alharthi,
- Abdullah F. Alharthi,
- Jahad Alghamdi,
- Ahad Alawad,
- Rand Alotaibi,
- Abdullah Kharbosh,
- Hessa Al Muqati,
- Abdulmohsen Alhuwahmel,
- Mohammed Almusallam,
- Ghada Albarrak,
- Ibrahim Al Sulaihim,
- Bader Alanazi,
- Bodoor S. Al-Dosari,
- Ramesh Vishwakarma,
- Alawi S. Alsaeedi,
- Alawi S. Alsaeedi,
- Alawi S. Alsaeedi,
- Ghassan Al Ghamdi,
- Ghassan Al Ghamdi,
- Ghassan Al Ghamdi,
- Hadeel Alkofide,
- Hasan M. Al-Dorzi,
- Hasan M. Al-Dorzi,
- Hasan M. Al-Dorzi
Affiliations
- Khalid Al Sulaiman
- Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia
- Khalid Al Sulaiman
- College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Khalid Al Sulaiman
- King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard—Health Affairs, Riyadh, Saudi Arabia
- Khalid Al Sulaiman
- Saudi Critical Care Pharmacy Research (SCAPE) Platform, Riyadh, Saudi Arabia
- Ohoud Aljuhani
- Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
- Ghazwa B. Korayem
- Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia
- Ali F. Altebainawi
- Pharmaceutical Care Services, King Salman Specialist Hospital, Hail Health Cluster, Hail, Saudi Arabia
- Shmeylan Al Harbi
- Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia
- Shmeylan Al Harbi
- College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Shmeylan Al Harbi
- King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard—Health Affairs, Riyadh, Saudi Arabia
- Abdulrahman Al Shaya
- Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia
- Abdulrahman Al Shaya
- College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Abdulrahman Al Shaya
- King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard—Health Affairs, Riyadh, Saudi Arabia
- Hisham A. Badreldin
- Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia
- Hisham A. Badreldin
- College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Hisham A. Badreldin
- King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard—Health Affairs, Riyadh, Saudi Arabia
- Raed Kensara
- Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia
- Raed Kensara
- King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard—Health Affairs, Riyadh, Saudi Arabia
- Abdullah F. Alharthi
- Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia
- Abdullah F. Alharthi
- King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard—Health Affairs, Riyadh, Saudi Arabia
- Jahad Alghamdi
- King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard—Health Affairs, Riyadh, Saudi Arabia
- Ahad Alawad
- Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia
- Rand Alotaibi
- Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia
- Abdullah Kharbosh
- Clinical Pharmacy Department, Pharmacy College, Taif University, Taif, Saudi Arabia
- Hessa Al Muqati
- Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia
- Abdulmohsen Alhuwahmel
- College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Mohammed Almusallam
- College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Ghada Albarrak
- Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia
- Ibrahim Al Sulaihim
- Pharmaceutical Care Department, Presidency of State Security, Central Security Hospitals, Riyadh, Saudi Arabia
- Bader Alanazi
- Pharmaceutical Care Department, Presidency of State Security, Central Security Hospitals, Riyadh, Saudi Arabia
- Bodoor S. Al-Dosari
- 0Pharmaceutical Care Department, King Abdulaziz University Hospital, Jeddah, Saudi Arabia
- Ramesh Vishwakarma
- 1Statistics Department, European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium
- Alawi S. Alsaeedi
- King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard—Health Affairs, Riyadh, Saudi Arabia
- Alawi S. Alsaeedi
- 2Intensive Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia
- Alawi S. Alsaeedi
- 3College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Ghassan Al Ghamdi
- King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard—Health Affairs, Riyadh, Saudi Arabia
- Ghassan Al Ghamdi
- 2Intensive Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia
- Ghassan Al Ghamdi
- 3College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Hadeel Alkofide
- 4Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
- Hasan M. Al-Dorzi
- King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard—Health Affairs, Riyadh, Saudi Arabia
- Hasan M. Al-Dorzi
- 2Intensive Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia
- Hasan M. Al-Dorzi
- 3College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- DOI
- https://doi.org/10.3389/fpubh.2022.877944
- Journal volume & issue
-
Vol. 10
Abstract
BackgroundThe cardiovascular complications of Coronavirus Disease 2019 (COVID-19) may be attributed to the hyperinflammatory state leading to increased mortality in patients with COVID-19. HMG-CoA Reductase Inhibitors (statins) are known to have pleiotropic and anti-inflammatory effects and may have antiviral activity along with their cholesterol-lowering activity. Thus, statin therapy is potentially a potent adjuvant therapy in COVID-19 infection. This study investigated the impact of statin use on the clinical outcome of critically ill patients with COVID-19.MethodsA multicenter, retrospective cohort study of all adult critically ill patients with confirmed COVID-19 who were admitted to Intensive Care Units (ICUs) between March 1, 2020, and March 31, 2021. Eligible patients were classified into two groups based on the statin use during ICU stay and were matched with a propensity score based on patient's age and admission APACHE II and SOFA scores. The primary endpoint was in-hospital mortality, while 30 day mortality, ventilator-free days (VFDs) at 30 days, and ICU complications were secondary endpoints.ResultsA total of 1,049 patients were eligible; 502 patients were included after propensity score matching (1:1 ratio). The in-hospital mortality [hazard ratio 0.69 (95% CI 0.54, 0.89), P = 0.004] and 30-day mortality [hazard ratio 0.75 (95% CI 0.58, 0.98), P = 0.03] were significantly lower in patients who received statin therapy on multivariable cox proportional hazards regression analysis. Moreover, patients who received statin therapy had lower odds of hospital-acquired pneumonia [OR 0.48 (95% CI 0.32, 0.69), P < 0.001], lower levels of inflammatory markers on follow-up, and no increased risk of liver injury.ConclusionThe use of statin therapy during ICU stay in critically ill patients with COVID-19 may have a beneficial role and survival benefit with a good safety profile.
Keywords